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ABSTRACT
Introduction: Patients with human
immunodeficiency virus (HIV) infection have
an increased risk of cardiovascular disease
(CVD). While viral suppression with
antiretroviral therapy decreases CVD risk
overall, several studies have suggested that
certain antiretrovirals, particularly certain
protease inhibitors, may be associated with an
increased relative risk of CVD. In AIDS Clinical
Trials Group 5260 s, ritonavir-boosted
atazanavir (ATV) was associated with slower
atherosclerosis progression compared to
ritonavir-boosted darunavir and raltegravir,
potentially due to hyperbilirubinemia.
Although hyperbilirubinemia may lead to
increased rates of treatment discontinuation, it
may also contribute to a favorable
cardiovascular (CV) profile for ATV. To fully
elucidate the effect of ATV on CVD risk among
HIV-infected patients, a systematic review of
the literature was performed.
Methods: A systematic search of the PubMed
and Embase databases was conducted on August
26, 2015, using terms to identify papers that
discuss ATV, HIV, and CVD. Articles were
limited to English-language publications of
randomized-controlled or observational studies
investigating adult humans. The primary
outcome was the incidence of CVD. Articles
describing surrogate markers of CVD were also
included.
Results: Ten studies were included in this
qualitative analysis: six reported CVD
outcomes, two reported data on atherosclerosis
as assessed by carotid intima-media thickness
(cIMT), and two reported outcomes related to
endothelial function. The studies reporting the
incidence of myocardial infarction (MI) among
HIV-infected patients showed that ATV
(boosted and unboosted) was not associated
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with an increased risk of acute MI. Other CV
endpoints were similarly unaffected by
treatment with ATV. Compared with
non-ATV-based regimens, ATV had beneficial
effects on cIMT progression in the publications
identified, with no apparent impact on
endothelial function.
Conclusions: This analysis showed that there
was no increased risk or occurrence of adverse
CV events among HIV-infected patients
receiving ATV. Markers of atherosclerosis were
improved, suggesting a possible antioxidant
effect of ATV, and endothelial function was
not affected.
Funding: Bristol-Myers Squibb (article
processing charges and medical writing
support).
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INTRODUCTION
Advances in antiretroviral therapy (ART) for the
treatment of human immunodeficiency virus
(HIV) have meant that patients can achieve a
life expectancy near to normal [1]. However,
HIV-infected patients are known to have an
increased risk of cardiovascular disease (CVD)
compared with the general population, with a
significantly elevated mortality rate from
cardiovascular (CV) events [2].
The cause of the increased CVD risk in
HIV-infected patients is multifactorial,
involving traditional CVD risk factors, HIV
infection-associated risk factors, and ART-
associated risk factors [3–6]. With improved life
expectancy, increased exposure to traditional
CVD risk factors, such as tobacco use,
dyslipidemia, hypertension, and diabetes, occurs
[3]. HIV infection is associated with increased
inflammation, immune dysfunction, and
impaired fibrinolysis [5]. While viral suppression
with ART has been associated with an overall
reduced risk of CVD events compared to
untreated HIV [7], several studies have suggested
that certain antiretrovirals (ARs) are associated
with an increased relative risk of CVD [3, 8–10],
possibly linked to factors, such as the
development of insulin resistance, dyslipidemia,
and altered fat distribution [6]. Abacavir (ABC),
didanosine, indinavir, and ritonavir-boosted
lopinavir (LPV/r) have been shown to be
associated with an increased risk of myocardial
infarction (MI) [8, 10]. Some studies suggest an
association between protease inhibitors (PIs) as a
drug class and increased CV events among
HIV-infected patients, which may be
attributable to the proatherogenic effect of these
agents on lipids [3, 9]. Importantly, these early
studies did not differentiate between different
types of PIs. Other analyses investigating CV risk
and PIs have been mixed, with observational
trials, but not randomized studies, indicating a
relationship between some PIs and increased risk
of CVD [8].
In contrast, the PI atazanavir (ATV) is
associated with improved lipid profiles, both in
patients with HIV and those with type 1 diabetes
without HIV, and improved endothelial
function in patients with type 2 diabetes
without HIV [11–13]. Ritonavir-boosted ATV
(ATV/r) has also been associated with slower
progression of carotid intima-media thickness
(cIMT)—a surrogate marker for CVD risk—
compared with ritonavir-boosted darunavir
(DRV/r) and raltegravir (RAL) [14], potentially
due to increased bilirubin caused by ATV.
Bilirubin is a known antioxidant that has
anti-atherosclerotic properties [15]. At the
same time, ATV-associated hyperbilirubinemia
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may lead to increased treatment
discontinuations, as was shown in AIDS
Clinical Trials Group (ACTG) A5257, where
ATV/r was equivalent to DRV/r and RAL in risk
for virologic failure, but was associated with
more discontinuations due to adverse events,
leading to the overall inferiority [16].
To fully elucidate the effect of ATV onCVD risk
amongHIV-infectedpatients soas toenableamore
complete assessment of its risk/benefit profile, a
systematic review of the literature was performed.
Theaimof thisqualitative analysiswas toassessCV
outcomes among patients with HIV treated with
ATV, using both CV event and surrogate marker
data, where available. Surrogate markers of
atherosclerosis and endothelial dysfunction were
included, as both have shown to be independent
predictors of CV events [17–20].
MATERIALS AND METHODS
Search Criteria
The PubMed and Embase databases were used for
the literature search, which was conducted on
August 26, 2015. The PubMed search was
performed using free text fields and Medical
Subject Heading terms to capture studies in
patients with HIV infection receiving ART who
had experienced adverse CV events (such as
coronary artery disease, MI, ischemia, angina,
cerebrovascular accident, transient ischemic
attack, or peripheral vascular disease). A similar
searchwas conducted using Embase. For detailed
terms used, see the Supplementary Material.
For both searches, citations were limited to
English-language articles with a publication type
of clinical trial, meta-analysis, observational
study, cohort study, or case–control study
investigating adult humans; no date restriction
was placed on the searches. The reference lists of
all included papers were hand-searched to
identify additional papers. While systematic
reviews and meta-analyses were not included in
the qualitative analysis, the reference lists of these
articles were hand-searched to ensure all eligible
studies were identified.
Study Selection
Study selection occurred in a two-step process: (1)
eligibility was initially assessed using titles and
abstracts and (2) those that were not excluded
were screened for inclusion/exclusion using the
full text. Articles excluded from the analysis were
retrospective studies, narrative reviews, editorials,
pharmacokinetic studies, pilot studies, animal or
in vitro studies, studies in children, and studies in
which only the change in lipid profile was
reported. Studies of patient subpopulations were
excluded unless the population characteristics
were generalizable to the adult HIV population.
Studies without an ATV arm and those not
reporting on outcomes of interest were excluded.
The primary outcome was the incidence of
CVD or CV event, defined as coronary heart
or artery disease, MI, acute coronary
syndrome, thromboembolism, stroke or
cerebrovascular events, atherosclerosis, and
coronary procedures, such as percutaneous
coronary intervention and coronary artery
bypass graft. Articles describing surrogate
markers of atherosclerosis and endothelial
function were also included.
Data Extraction and Assessment of Study
Quality
Data collected from the articles included study
description and trial characteristics, patient
characteristics, treatment characteristics, and
results/endpoints. Data extraction and
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validation were performed by MG and LR,
respectively. The results of the data extraction
were independently reviewed by DC and CS
prior to commencing writing of the article. The
quality of the included studies was assessed
using the methodology checklist of the 2012
National Institute for Health and Care
Excellence Guidelines Manual [21] for the
randomized-controlled trials and the ‘checklist
for measuring study quality’ [22] for the cohort
studies.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
A preferred reporting items for systematic
reviews and meta-analyses flow diagram
showing the screening process and reasons for
exclusion is presented in Fig. 1. A total of 24
studies were identified using PubMed, 77 were
identified using Embase, and five were
identified from hand searching the reference
lists of identified articles. The major reason for
excluding articles during the first screening
round was that they were not a clinical or
cohort study; during the second round of
screening, not reporting an outcome of
interest was the main reason for article
exclusion. In total, ten studies met all criteria
and were included in the qualitative analysis
(Fig. 1). Among the included studies, the length
of follow-up ranged from 1.5 to 4.8 years, and
the studies varied greatly with respect to the
ATV-containing and comparator regimens used
(Tables 1, 2, 3).
Quality assessment of the included studies is
shown in detail in the Supplementary Material.
The included randomized-controlled trials were
of moderate quality, mainly because they were
either fully open-label studies [14, 23–25] or
were only partially blinded to one component
of the AR regimen [26] or to observers [27]. In
addition, one trial showed a significant
elevation in triglycerides at baseline in the
ATV arm [27] and two trials showed an
imbalance in discontinuation rates between
the ATV and comparator arms [14, 24]. The
included cohort studies were of moderate
quality, mainly due to the lack of information
on patients lost to follow-up, on the
representativeness of the study populations
and on-treatment compliance.
Of the ten articles included, six reported
CVD outcomes [24–26, 28–30], two reported
data on atherosclerosis as assessed by the
surrogate marker cIMT [14, 31], and two
reported outcomes related to endothelial
function [23, 27]. Data were insufficient and
outcomes were too varied to conduct a
quantitative meta-analysis or to make
systematic comparisons between ATV and
other ARTs. Therefore, data were compiled
qualitatively.
Effect of ATV on CVD Outcomes
Of the studies reporting CV outcomes, three
were cohort studies and three were
randomized-controlled trials (Table 1). Four of
the studies included only treatment-naı¨ve
patients [24–26, 28], one included both
treatment-experienced and -naı¨ve patients
[30], and one included only
treatment-experienced patients [29]. The
results of these studies are reported in Table 1.
The studies reporting the incidence of MI in
HIV-infected patients showed that ATV was not
476 Infect Dis Ther (2016) 5:473–489
associated with an increased risk of acute MI. In
a cohort of [16,000 treatment-naı¨ve patients,
patients initially treated with both boosted and
unboosted ATV (n = 543; inverse probability
weighted hazard ratio: 1.12; 95% CI 0.35–3.62)
or LPV/r (n = 654; 0.92; 95% CI 0.26–3.22) did
not have an increased rate of MI compared with
the initial treatment with a non-nucleoside
reverse-transcriptase inhibitor, whereas
patients initially treated with ABC (n = 611;
2.05; 95% CI 0.72–5.86) trended towards an
increased rate of MI compared with tenofovir
disoproxil fumarate (TDF) [28]. Data from the
treatment-naı¨ve and -experienced patients
included in the D:A:D (Data Collection on
Adverse Events of Anti-HIV Drugs) study
showed no relationship between ATV exposure
(37,005 patient years) and an increased MI risk
among HIV-infected patients compared with
other AR agents, either overall (relative rate/
year 0.95; 95% CI 0.86–1.04) or when ATV was
given with or without ritonavir (0.99; 95% CI
Records identified through 
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Fig. 1 PRISMA ﬂow diagram of the study selection process
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0.90–1.08 and 0.80; 95% CI 0.61–1.03,
respectively) [30]. In the Durand et al. study, a
cohort and nested control analysis of a public
health insurance database included 7053
HIV-positive patients, and treatment-
experienced patients exposed to ATV with and
without ritonavir (number exposed to ATV
unknown) did not have an increased risk of
MI compared with controls without ATV
exposure (p = 0.96; Table 1) [29]. In this
analysis, HIV-infected patients exposed to
ABC, LPV, or ritonavir had an increased risk of
acute MI (odds ratios 1.79, 1.98, and 2.29,
respectively; p\0.01 vs. matched controls) [29].
Other CV endpoints were similarly
unaffected by treatment with ATV. The D:A:D
study examined the risk of stroke among
HIV-infected patients exposed to ATV and
found no association between ATV and an
increased stroke risk (overall 0.95; 95% CI
0.87–1.05; boosted 1.02; 95% CI 0.98–1.06;
unboosted 0.80; 95% CI 0.61–1.03) [30]
(Table 1).
Of the three randomized-controlled trials
reporting a variety of CV endpoints (a
composite of coronary artery disease, infarct,
ischemia, angina, transient ischemic attack,
cerebrovascular accident, or peripheral
vascular disease [26] or unspecified CV adverse
events [24, 25]), there was no increase in CV
events among HIV-infected patients receiving
ATV (n = 1141). In the ACTG study A5202,
there was a low incidence of CV events overall
in patients receiving ABC/lamivudine or TDF/
emtricitabine (FTC) plus ATV/r or efavirenz,
with no difference between treatment groups
[26]. In the studies reporting unspecified CV
adverse events, there was one occurrence each
of MI and cardiac failure among patients
receiving ATV/r and one occurrence each of
angina pectoris and myopericarditis among
patients receiving nevirapine through 4 years
of follow-up (Table 1) [24], and in the
randomized open-label ARIES study
(ClinicalTrials.gov identifier: NCT00440947),
one occurrence of cerebrovascular accident
and one of peripheral vascular disease in
treatment-naı¨ve patients treated with ATV
with or without ritonavir in combination with
ABC/lamivudine [25].
Effect of ATV on Markers
of Atherosclerosis
Two studies investigated the effect of ATV on
atherosclerosis using changes in cIMT. One was a
prospective, randomized-controlled ACTG
substudy (A5260 s) in treatment-naı¨ve patients,
while the other was a single-center, prospective
matched-control cohort study in treatment-
experienced patients (Table 2) [14, 31].
Overall, the results of the cIMT
measurements showed that treatment with
ATV was associated with beneficial effects on
cIMT progression compared with
non-ATV-based regimens (Table 2). In the
ACTG 5260 s study, patients received either
TDF/FTC plus either ATV/r (n = 109), DRV/r
(n = 113), or RAL (n = 106) for 144 weeks. At
study end, increases in cIMT at the common
carotid artery (primary intent-to-treat analysis)
had progressed more slowly in patients
receiving ATV/r than in those receiving DRV/r
or RAL; however, differences reached statistical
significance in the comparison with DRV/r
(p = 0.013) but not with RAL (p = 0.15) [14]. In
the on-treatment analysis and at the carotid
bifurcation, ATV/r was associated with
significantly slower cIMT progression
compared with both DRV and RAL [14]. In the
cohort study, patients receiving regimens,
including ATV/r (n = 33), had significantly
decreased cIMT compared with matched
controls not receiving ATV/r (n = 99) after 12
484 Infect Dis Ther (2016) 5:473–489
and 18 months of therapy (p B 0.05 for both)
[31]. The differences in cIMT progression
remained significant after adjustment for
differences in baseline demographics.
Effect of ATV on Endothelial Function
Two randomized-controlled trials in treatment-
experienced patients with HIV assessed
endothelial function via flow-mediated dilation
(FMD) of the brachial artery [23, 27] (Table 3).
There was no impact of ATV therapy on
endothelial function in these studies (Table 3).
Both the randomized-controlled trials
investigated switching from another PI to ATV
(with or without ritonavir) with a trial duration
of 24 weeks. Inpatients receivingunboostedATV
(n = 20), there was no change in FMD compared
with the previous PI therapy (p = 0.40) [27], and
patients receiving ATV/r (n = 26) did not
demonstrate any significant change in FMD
both from baseline and versus patients
continuing on the previous PI/r therapy
(p = 0.64 after adjustment for brachial artery
diameter changes) [23]. Endothelial function
was also measured in the ACTG A5260 s study.
FMD did not change significantly among
patients treated with ATV/r, RAL, or DRV/r. In
addition, despite the differences seen in cIMT
progression, there were no differences in FMD
change between treatment arms [14].
DISCUSSION
This systematic literature review concerning
ATV and CVD risk among patients with HIV
showed no relationship between boosted and
unboosted ATV and an increased risk for CV
clinical outcome events, including MI and
stroke. The use of ATV was associated with
improvements in surrogate markers of
atherosclerosis compared with non-ATV-based
regimens, and the studies analyzed showed no
impact of ATV on endothelial function.
This study did not investigate the impact of
ATV on lipid levels in HIV-infected patients, as
previous studies have explored this [11, 32]. In
one systematic study, ATV was associated with
lower lipid levels compared with a pooled
cohort of other ritonavir-boosted PI regimens
[11]. A second study of ritonavir-boosted PIs
found that patients treated with ATV had
cholesterol and triglyceride elevations that
were lower than LPV or fosamprenavir but
similar to saquinavir or DRV [32]. It is not
entirely clear what contributions lipid
elevations make to the overall CV risk. In the
ACTG A5260 s study, ATV/r was associated with
slower atherosclerosis progression compared to
DRV/r and RAL, despite RAL having smaller
increases in lipid parameters than the boosted
PI arms [14].
One potential explanation for this
apparent discrepancy is ATV-induced
hyperbilirubinemia, which is a common
laboratory abnormality associated with ATV
treatment. Bilirubin has been shown to have
antioxidant, anti-inflammatory, and
antiatherogenic properties and is thought to
result in protection from CVD [33, 34]. Multiple
studies have shown that individuals with
Gilbert syndrome, a genetic deficiency in
UGT1A1 resulting in chronic low level
hyperbilirubinemia, have a reduced risk for CV
events compared with the general population
[35–38]. ATV has been shown to increase
bilirubin levels and reduce levels of oxidative
stress in HIV-infected patients compared with
non-ATV-based treatment [23, 39]. Additional
studies have also linked increasing bilirubin
levels with slower atherosclerosis progression
(as measured by cIMT) [14, 40], which suggests
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that there may be a relationship between ATV
therapy, bilirubin levels and improvements in
oxidative stress, atherosclerosis, and CV risk.
Due to its impact on bilirubin and the
anti-atherosclerotic properties of bilirubin,
ATV has been studied in non-HIV-infected
patients with type 1 and 2 diabetes. In
patients with type 1 diabetes, the initiation of
ATV decreased lipid parameters and increased
total plasma antioxidant capacity from baseline;
however, similar to the studies of HIV-infected
patients analyzed in this review, it did not result
in an improvement in endothelial function
[12]. In an experimental double-blind,
placebo-controlled crossover study of
HIV-negative patients with type 2 diabetes,
ATV was associated with a significant
improvement in both plasma antioxidant
capacity and endothelial function [13].
Recent studies published after the search for
this analysis was initiated are consistent with
the results described here. In an analysis of data
from HIV-infected patients in the Veterans
Health Administration Clinical Case Registry,
exposure to ATV was not associated with an
increased risk of CV events [41]. Moreover, in a
retrospective, longitudinal study of patients
with HIV in Brazil, the recent boosted ATV
exposure was associated with a decreased risk of
CV outcome events [42]. Finally, in a
retrospective analysis of the Hawaii Aging with
HIV CV Study, patients receiving ATV/r had a
slower progression of cIMT over 2 years
compared with those not receiving ATV/r
(9 lm vs. 22 lm; p\0.001). These differences
remained significant after adjusting for age, sex,
and other CVD-related comorbidities
(p = 0.012). Similar to the ACTG A5260 s study,
there was a significant inverse correlation
between increasing baseline total serum
bilirubin and reduced cIMT progression [40].
This analysis has limitations. First, a small
number of studies were identified with
relatively few ATV patients. This combined
with the variable forms of data presentation
and outcomes prevented a meta-analysis from
being performed. Second, data were insufficient
to make any assessment of differences in CV
outcomes with unboosted ATV versus
ritonavir-boosted ATV. Third, studies solely
investigating lipid levels were not included,
and no attempt was made to account for
concomitant medications, such as statins, or
baseline comorbidities, or to weight evidence
according to its source, i.e., from
randomized-controlled studies or from studies
performed under real-world conditions. Fourth,
patients included in these analyses had variable
durations of HIV infection, AR experience, and
were exposed to a wide variety of ART regimens.
Given the relatively limited information
identified in this review, larger cohort studies
are needed to better evaluate the relative risk of
CVD with ATV versus other contemporary ARs
in patients with HIV infection.
CONCLUSIONS
In this systematic review of CVD in
HIV-infected patients receiving ATV, a limited
number of studies were identified. In the
identified studies, there was no increase in the
risk or occurrence of adverse CV clinical
outcome events with boosted and unboosted
ATV compared to other AR agents. Endothelial
function was not affected by ATV, while ATV
use was associated with improvements in
markers of atherosclerosis. These findings
should be taken into consideration when
selecting HIV treatment for individuals at
increased risk of CVD.
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